


HEALTHCARE CONFERENCE 2025



BELL POTTER

Day 1: Tuesday, 18 November

8:25AM INTRODUCTION

8:30AM 4DMEDICAL (4DX)

9:00AM NANOSONICS (NAN)

9:30AM POLYNOVO (PNV)

10:00AM AROA BIOSURGERY (ARX)

10:25AM MORNING TEA

10:30AM GENETIC SIGNATURES (GSS)

11:00AM INOVIQ (IIQ)

11:30AM CLINUVEL PHARMACEUTICALS (CUV)

12:00PM MICROBA LIFE SCIENCES (MAP)

12:30PM LUNCH

1:00PM NOVA EYE MEDICAL (EYE)

1:30PM ONEVIEW HEALTHCARE (ONE)

2:00PM AUSTCO HEALTHCARE (AHC)

2:30PM TRAJAN (TRJ)

2:55PM AFTERNOON TEA

3:00PM ALCIDION (ALC)

3:30PM PHARMX TECHNOLOGIES (PHX)

4:00PM MACH7 TECHNOLOGIES (M7T)

4:30PM PRO MEDICUS (PME)

4:55PM WRAP-UP


Session 1

Session 2

Session 3

Session 4

HEALTHCARE CONFERENCE 2025



Day 2: Wednesday, 19 November

8:25AM INTRODUCTION

8:30AM IMPEDIMED (IPD)

9:00AM LTR PHARMA (LTP)

9:30AM MEDICAL DEVELOPMENTS (MVP)

10:00AM BIOME (BIO)

10:25AM MORNING TEA

10:30AM RADIOPHARM THERANOSTICS (RAD)

11:00AM CYCLOPHARM (CYC)

11:30AM CLARITY PHARMACEUTICALS (CU6)

12:00PM TELIX PHARMACEUTICALS (TLX)

12:30PM LUNCH

1:00PM ACTINOGEN MEDICAL (ACW)

1:30PM ALTERITY THERAPEUTICS (ATH)

2:00PM AMPLIA THERAPEUTICS (ATX)

2:30PM IMUGENE (IMU)

2:55PM AFTERNOON TEA

3:00PM EBR SYSTEMS (EBR)

3:30PM EMVISION MEDICAL DEVICES (EMV)

4:00PM ANTERIS TECHNOLOGIES (AVR)

4:30PM IMRICOR MEDICAL SYSTEMS (IMR)

4:55PM WRAP-UP


Session 1

Session 2

Session 3

Session 4

HEALTHCARE CONFERENCE 2025



BELL POTTER

Day 3: Thursday, 20 November

8:25AM INTRODUCTION

8:30AM SYNTARA (SNT)

9:00AM IMMUTEP (IMM)

9:30AM IMMVIRX

10:00AM MESOBLAST (MSB)

10:25AM MORNING TEA

10:30AM SALUDA MEDICAL

11:00AM CYNATA THERAPEUTICS (CYP)

11:30AM POLYACTIVA

12:00PM ORTHOCELL (OCC)

12:30PM LUNCH

1:00PM PROTEOMICS INTERNATIONAL (PIQ)

1:30PM VITRAFY LIFE SCIENCES (VFY)

2:00PM QBIOTICS

2:30PM ARTRYA (AYA)

2:55PM AFTERNOON TEA

3:00PM ONCOSIL MEDICAL (OSL)

3:30PM PYC THERAPEUTICS (PYC)

4:00PM PARADIGM BIOPHARMACEUTICALS (PAR)

4:30PM STARPHARMA (SPL)

4:55PM WRAP-UP


Session 1

Session 2

Session 3

Session 4

HEALTHCARE CONFERENCE 2025



BELL POTTER

Day 1: Tuesday, 18 November

8:30AM

4DMEDICAL (4DX)

4DMedical is a global MedTech company advancing respiratory care with AI-driven imaging. Its portfolio includes FDA-cleared XV LVAS® and CT LVAS™, anchored by CT:VQ™—a ground-breaking, non-contrast ventilation and perfusion solution redefining cardiothoracic imaging. Delivered via SaaS, 4DMedical empowers earlier diagnosis, precision treatment, and improved patient outcomes.

Market cap \$840.8M

9:00AM

NANOSONICS (NAN)

Nanosonics is a global infection prevention company headquartered in Sydney, Australia. It designs, manufactures and distributes innovative automated disinfection technologies, including its flagship Trophon system for high-level disinfection of ultrasound probes. Nanosonics partners with major healthcare providers worldwide to improve patient safety and reduce hospital-acquired infection risks.

Market cap \$1.3B

9:30AM

POLYNOVO (PNV)

PolyNovo is an Australian medical technology company specialising in advanced wound care and reconstructive solutions. Its proprietary NovoSorb biodegradable polymer platform is used in products like NovoSorb BTM to aid skin regeneration after burns, trauma, and surgery. PolyNovo markets globally, improving outcomes for patients with complex wounds.

Market cap \$853.2M


10:00AM

AROA BIOSURGERY (ARX)

Aroa Biosurgery is a high-growth medical technology company based in New Zealand. It develops, manufactures and sells innovative soft-tissue repair and wound-healing devices using its proprietary extracellular matrix (ECM) technology. Aroa's products are marketed globally, improving surgical outcomes and supporting regenerative healing across diverse clinical applications.

Market cap \$264.0M

HEALTHCARE CONFERENCE 2025



BELL POTTER

Day 1: Tuesday, 18 November

10:30AM

GENETIC SIGNATURES (GSS)

Genetic Signatures is a molecular diagnostics company developing innovation infectious disease testing solutions. Its 3base technology powers the EasyScreen real-time PCR platform, enabling rapid, accurate detection of multiple pathogens from a single sample. The company focuses on advancing global diagnostic efficiency across clinical and public health settings.

Market cap \$63.6M

11:00AM

INOVIQ (IIQ)

INOVIQ is a leader in exosome technology focused on advancing next-generation diagnostics and therapeutics that transform cancer care and improve patient outcomes. Our product portfolio spans commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical-stage CAR-exosome therapeutic program targeting solid tumours.

Market cap \$48.6M

11:30AM

CLINUVEL PHARMACEUTICALS (CUV)

Clinvuel Pharmaceuticals is a global specialty biopharmaceutical company developing and commercialising therapies for genetic, metabolic, and life-threatening disorders. A leader in photomedicine and melanocortin science, Clinvuel's innovations address unmet needs in systemic photoprotection, DNA repair, and repigmentation for patients lacking effective treatment alternatives.

Market cap \$554.2M


12:00PM

MICROBA LIFE SCIENCES (MAP)

Microba Life Sciences is a commercial-stage biotechnology company advancing microbiome testing and therapeutics to transform chronic disease diagnosis and treatment. Leveraging its proprietary analysis platform and partnerships, including with Sonic Healthcare, Microba is rapidly expanding internationally to lead the emerging \$100 billion global microbiome diagnostics and therapeutics market.

Market cap \$45.1M

HEALTHCARE CONFERENCE 2025



BELL POTTER

Day 1: Tuesday, 18 November

1:00PM

NOVA EYE MEDICAL (EYE)

Nova Eye Medical develops and commercialises innovative ophthalmic treatment technologies for glaucoma and age-related eye diseases. The company's proprietary iTrack™ and Molteno3® devices are used globally by ophthalmologists to restore and preserve vision, providing effective minimally invasive options that address a leading cause of irreversible blindness.

Market cap \$38.5M

1:30PM

ONEVIEW HEALTHCARE (ONE)

OneView Healthcare provides a cloud-based platform unifying hospital systems, content, and services at the point of care. Its technology empowers patients, streamlines workflows for care teams, and simplifies operations for executives. Partnering with major healthcare systems globally, OneView enhances engagement and efficiency across more than 80 hospitals worldwide.

Market cap \$172.2M

2:00PM

AUSTCO HEALTHCARE (AHC)

Austco Healthcare is a global provider of innovative clinical communication solutions, including Tacera Workflow, Pulse Mobile, RTLS, and Patient Information Boards. In FY25, Austco delivered record revenue of \$81.4m (+40%) and EBITDA of \$13.0m (+62%), driven by strategic acquisitions, product innovation, and accelerating global market expansion.

Market cap \$161.1M

2:30PM

TRAJAN (TRJ)

Trajan develops and manufactures analytical and life-science instrumentation, consumables, and automation systems for biological, food, environmental and diagnostics workflows. The company serves global markets from sites across the US, Europe, Australia and Asia, and is scaling its disruptive technology portfolio.

Market cap \$111.4M

HEALTHCARE CONFERENCE 2025

Day 1: Tuesday, 18 November

3:00PM **ALCIDION (ALC)**

Alcidion's platform, Miya Precision, leverages cutting edge technology to support better digitally enabled care that improves efficiencies in clinical decision making, with a focus of helping healthcare providers manage patient information, streamline clinical workflows, and make better informed decisions about patient care.

Market cap \$119.5M

3:30PM **PHARMX TECHNOLOGIES (PHX)**

PharmX Technologies is a company that sits at the heart of the pharmacy network, providing critical cloud-based infrastructure that connects pharmacies, wholesalers, suppliers, and government. Its Gateway, Portal, Data, and eCommerce solutions streamline inventory management and enable smarter decisions, processing over A\$20 billion in orders annually across 99% of ANZ pharmacies.

Market cap \$89.9M

4:00PM **MACH7 TECHNOLOGIES (M7T)**

Mach7 Technologies is a leading provider of medical imaging software, delivering advanced data management and diagnostic viewing solutions to healthcare organisations worldwide. The Mach7 Enterprise Imaging Solution (EIS) is a next-generation solution combining a powerful Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer, and robust diagnostic workflow applications.


Market cap \$72.8M

4:30PM **PRO MEDICUS (PME)**

Pro Medicus is a global healthcare informatics company delivering advanced medical imaging solutions through its Visage 7 platform. Offering RIS, PACS, AI, and e-health technologies, Pro Medicus enables ultra-fast, cloud-based image viewing and analysis for hospitals and imaging centres worldwide, enhancing diagnostic precision and clinical efficiency.

Market cap \$26.7B

HEALTHCARE CONFERENCE 2025



BELL POTTER

Day 2: Wednesday, 19 November

8:30AM IMPEDIMED (IPD)

ImpediMed is a company that designs and manufactures medical technologies using bioimpedance spectroscopy (BIS) and digital health platforms for non-invasive monitoring of body fluid and composition. Its FDA-cleared SOZO system enables early detection and prevention of breast cancer-related lymphedema, supports weight management, and aids clinicians in monitoring heart failure patients.

Market cap \$73.2M

9:00AM LTR PHARMA (LTP)

LTR Pharma is a company advancing a proprietary intranasal platform with commercial traction in Australia and global growth plans. Its lead products, SPONTAN® and ROXUS®, treat erectile dysfunction in under 10 minutes, while the pipeline candidate, OROFLOW®, targets oesophageal motility disorders, addressing significant unmet medical needs.

Market cap \$52.9M

9:30AM MEDICAL DEVELOPMENTS (MVP)

Medical Developments is a leader in emergency pain management, best known for Pentrox (“The Green Whistle”), an inhaled analgesic used in over 30 countries including Australia, the UK, and France. The company also produces respiratory products supporting patients with asthma and chronic obstructive pulmonary disease (COPD).


Market cap \$66.5M

10:00AM BIOME (BIO)

Biome is a health science company focused on developing, manufacturing, and commercialising evidence-based biotherapeutic and nutraceutical solutions. Integrating research, clinical validation, and commercial expertise, Biome aims to advance gut and systemic health through innovation probiotic technologies, expanding its footprint across healthcare, pharmacy, and practitioner networks globally.

Market cap \$99.3M

HEALTHCARE CONFERENCE 2025



Day 2: Wednesday, 19 November

10:30AM **RADIOPHARM THERANOSTICS (RAD)**

Radiopharm Theranostics is a clinical-stage biotechnology company developing first-in-class radiopharmaceuticals for both diagnostic imaging and therapeutic applications in oncology. The company is advancing a pipeline of antibody, nanobody, peptide and small-molecule platforms targeting cancers with high unmet medical need.

Market cap \$64.0M

11:00AM **CYCLOPHARM (CYC)**

Cyclopharm is an Australian radiopharmaceutical company specialising in Technegas, a functional lung imaging system used in respiratory and nuclear medicine. Distributed in 66 countries, Technegas assists diagnosis of pulmonary embolism, COPD, asthma, and lung cancer. Following FDA approval, Cyclopharm is expanding its commercial footprint in the United States.

Market cap \$70.0M

11:30AM **CLARITY PHARMACEUTICALS (CU6)**

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.


Market cap \$1.7B

12:00PM **TELIX PHARMACEUTICALS (TLX)**

Telix is a global leader in radiopharmaceuticals, and its theranostic pipeline aims to address unmet medical needs in urologic, neurologic, musculoskeletal, and hematologic oncology. Telix's lead product for prostate imaging has been approved in Australia, Brazil, Canada, Europe, and the U.S. Telix's second-generation prostate imaging product has also been approved in the U.S.

Market cap \$5.1B

HEALTHCARE CONFERENCE 2025



Day 2: Wednesday, 19 November

1:00PM **ACTINOGEN MEDICAL (ACW)**

Actinogen is advancing a revolutionary oral therapeutic, Xanamem, through pivotal clinical trials to transform treatment for Alzheimer's disease and major depressive disorder. Its mission is to improve lives by targeting brain cortisol with precision and innovation. The Company is ASX-listed and has operations based in Australia and the US.

Market cap \$133.5M

1:30PM **ALTERITY THERAPEUTICS (ATH)**

Alterity Therapeutics is a late clinical-stage biotech company developing disease-modifying therapies for neurodegenerative disorders. Its lead asset, ATH434, targets Parkinsonian syndromes – notably Multiple System Atrophy (MSA) – and has secured U.S. Food and Drug Administration Fast track status.

Market cap \$97.9M

2:00PM **AMPLIA THERAPEUTICS (ATX)**

Amplia Therapeutics is developing the best-in-class small molecule FAK inhibitor for use in solid tumours. The Company has reported promising data from the ACCENT trial in pancreatic cancer. Additional data from this trial and a second trial in the US will be discussed, along with plans for follow-on studies.

Market cap \$66.7M

2:30PM **IMUGENE (IMU)**

Imugene is a clinical-stage immune-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Its pipeline includes allogeneic CAR T cell therapy, oncolytic viruses and B-cell vaccine platforms targeting both blood and solid tumours.

Market cap \$104.1M

HEALTHCARE CONFERENCE 2025

Day 2: Wednesday, 19 November

3:00PM **EBR SYSTEMS (EBR)**

EBR Systems develops leadless implantable cardiac devices using its proprietary WiSE CRT System technology, enabling wireless left-ventricular endocardial pacing for heart-failure and rhythm management. The company is focused on transforming cardiac resynchronisation therapy by eliminating pacing leads and improving patient outcomes.

Market cap \$526.4M

3:30PM **EMVISION MEDICAL DEVICES (EMV)**

EMVision Medical Devices is an Australian medical technology company developing portable, non-invasive brain imaging devices. Using advanced electromagnetic imaging, EMV aims to transform the rapid diagnosis and treatment of stroke and other time-critical neurological conditions, enabling affordable, safe, and accessible neurodiagnostics at the point of care.

Market cap \$167.3M

4:00PM **ANTERIS TECHNOLOGIES (AVR)**

Anteris Technologies is a structural heart company developing and commercialising its biomimetic DurAVR transcatheter heart-valve system, designed to mimic a health aortic valve. The company is headquartered in Australia with a significant U.S. presence and is advancing regulatory and clinical milestones globally.

Market cap \$107.6M

4:30PM **IMRICOR MEDICAL SYSTEMS (IMR)**

Imricor Medical Systems develops and manufactures MRI-compatible cardiac ablation devices, including its Vision-MR line and Advantage-MR EP system. Headquartered in the United States and listed in Australia, the company's technology enables real-time MRI-guided catheter ablation for arrhythmias, aiming to improve outcomes and reduce costs.

Market cap \$447.7M

HEALTHCARE CONFERENCE 2025

Day 3: Thursday, 20 November

8:30AM

SYNTARA (SNT)

Syntara is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. Lead candidate amsulostat is in phase 2 trials for the bone marrow cancer myelofibrosis.

Market cap \$47.3M

9:00AM

IMMUTEP (IMM)

Immutep is a clinical-stage biotechnology company pioneering immunotherapies that modulate the immune system to fight cancer and autoimmune diseases. Its diversified pipelines includes four clinical-stage candidates, led by efitlagimod alfa (efti) for oncology and IMP761 for autoimmune disorders, targeting the LAG-3 immune checkpoint pathway.

Market cap \$390.1M

9:30AM

IMMVIRX

ImmVirX is a clinical stage oncology company developing receptor targeted oncolytic RNA immunotherapies to enable powerful and durable responses in the most globally prevalent cancers with high unmet need.

10:00AM

MESOBLAST (MSB)

Mesoblast is a global leader in developing allogeneic, off-the-shelf cellular medicines for severe inflammatory diseases. Its FDA-approved therapy RYONCIL (Remestemcel-L) treats paediatric SR-aGvHD, with further programs targeting adult Sr-aGvHD and inflammatory bowel disease. Rexlemestrocel-L is in development for heart failure and chronic low back pain.

Market cap \$3.0B

HEALTHCARE CONFERENCE 2025

Day 3: Thursday, 20 November

10:30AM SALUDA MEDICAL

Saluda Medical is a commercial-stage medical-device company pioneering a closed-loop neuromodulation platform. Its flagship Evoke System for spinal-cord stimulation senses and adjusts neural activity in real time to treat chronic pain. In the U.S., the company secured FDA approval for its automated programming platform.

11:00AM CYNATA THERAPEUTICS (CYP)

Cynata is a clinical-stage biotechnology company transforming regenerative medicine through the proprietary Cymerus™ platform technology. Results of a Phase 2 trial in acute graft versus host disease (GvHD) and a Phase 3 trial in osteoarthritis are expected during the current financial year - building on previous positive clinical data in GvHD and diabetic foot ulcers.

Market cap \$54.6M

11:30AM POLYACTIVA


PolyActiva is a clinical-stage biopharmaceutical company developing novel drug delivery solutions to improve outcomes for patients with ocular conditions. The company's lead asset, PA5108, is a biodegradable ocular implant that delivers sustained latanoprost pro-drug (NCE) therapy to reduce intraocular pressure in glaucoma and ocular hypertension.

12:00PM ORTHOCELL (OCC)

Orthocell is a regenerative medicine company focused on regenerating mobility for patients. They develop products for the repair of a variety of bone, nerve and tendon injuries. Orthocell's portfolio of products include CelGro™ platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications.

Market cap \$299.3M

HEALTHCARE CONFERENCE 2025



BELL POTTER

Day 3: Thursday, 20 November

1:00PM

PROTEOMICS INTERNATIONAL (PIQ)

Proteomics is creating and commercialising tests at the forefront of predictive diagnostics and precision medicine, in diseases from diabetic kidney disease to oesophageal cancer and endometriosis. Our mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

Market cap \$55.7M

1:30PM

VITRAFY LIFE SCIENCES (VFY)

Vitrafy Life Sciences has developed a proprietary range of smart cryopreservation hardware and its LifeChain cloud-based software platform to deliver a complete cryopreservation solution. Combining advanced technology with seamless integration, Vitrafy ensures the preservation and integrity of sensitive biological materials, optimising storage and handling across life sciences industries.

Market cap \$61.8M

2:00PM

QBIOTICS

QBiotics is an Australian public unlisted life sciences company that specialises in the discovery and development of plant-derived small molecules to treat diseases of high unmet need. Their initial focus is oncology and wound healing. The lead asset, tigilanol tiglate, is currently in Phase IIa clinical trials, while EBC-1013 is in Phase I clinical trials.


2:30PM

ARTRYA (AYA)

Artrya is a medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary Salix software analyses coronary CT scans to identify key biomarkers, enabling faster, more accurate diagnosis. Artrya is advancing regulatory and commercial initiatives across global healthcare markets.

Market cap \$575.1M

HEALTHCARE CONFERENCE 2025



BELL POTTER

Day 3: Thursday, 20 November

3:00PM

ONCOSIL MEDICAL (OSL)

OncoSil Medical is a medical device company specialising in radiation therapy for the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device delivers targeted radioactive microparticles directly into pancreatic tumours. The treatment aims to improve treatment outcomes and enhance patient quality of life through precision oncology.

Market cap \$24.5M

3:30PM

PYC THERAPEUTICS (PYC)

PYC Therapeutics is a genetic medicine specialist developing a pipeline of RNA drugs for patients with severe unmet medical needs. The Company has 3 clinical-stage assets reading out on human efficacy within the next 12 months.

Market cap \$688.2M

4:00PM

PARADIGM BIOPHARMACEUTICALS (PAR)

Paradigm Biopharmaceuticals (ASX:PAR) is advancing a global Phase 3 trial of injectable PPS for knee osteoarthritis, with an interim analysis expected mid-2026. Fully funded to this milestone, iPPS offers year-long pain relief after one six-week course, strong safety data, FDA Fast-Track status, and potential disease-modifying benefits.

Market cap \$156.4M

4:30PM

STARPHARMA (SPL)

Starpharma is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Market cap \$138.0M

HEALTHCARE CONFERENCE 2025

Get in touch with your Bell Potter contact for conference access or call 1300 023 557.

Information relayed as part of the Conference is to be considered general investment advice only and does not constitute advice to any person. Although we believe that the advice and information which would be covered and/or provided as part of the Conference is reliable, Bell Potter Securities Limited has not independently verified information which is derived from publicly available sources, directors and management. As such, Bell Potter Securities Limited, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information that would be presented as part of the Conference is complete or accurate. Should you wish to consider and implement said information/advice, please assess the appropriateness of this information/advice with regard to your objectives, financial situation and needs, because the advice has not taken these factors into account. Bell Potter Securities Limited does not accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information presented to you as part of the Conference. Although we are elated to host you for another, please note that you are not under any obligation to attend the Conference.